Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban
This article was originally published in The Rose Sheet
Executive Summary
Hatch, primary author of the legislation Congress passed in 1994 as FDA's framework for regulating the supplement industry, notes in a letter that FDA did not question vinpocetine's safety in evaluations of five NDI notifications.